About Us
- member sign in
- About Us
- Stem Cells R&D
- Products and services
- Tissue & Cells Bank
- News
- Contact
Stem Cells R&D
Products and services
Stem Cells R&D
Products and services
Development history
Twenty-nine years have witnessed our development from being born to being transformed, from ignorance to maturity, and from being a boat to becoming a giant.
1.Ningxia Zhonglianda Biological Co., Ltd. (now renamed as China National Aviation (Ningxia) Biological Co., Ltd.) was formally established.
"Bone marrow blood, peripheral blood, umbilical cord blood cell processing kit" began research and development.
"A nuclear cell in vitro isolation kit and its application method" has been granted patent authorization.
"Nuclear cell processing kit" has been approved by Ningxia food and drug administration.
"A method for separating and extracting stem cells from the placenta, umbilical cord, or adipose tissue species" issued the patent in 2009
It’s approved "High-tech Enterprise in Ningxia Hui Autonomous Region " in 2011
Biomedical Engineering Academician Workstation in Ningxia Hui Autonomous Region was established in 2011
Our company has selected China Torch Program in 2012
AVIC Capital has controlled Ningxia Zhonglianda Biological Co., Ltd., the name of our company has changed to AVIC BIOLOGY in 2012
It’s approved " Medical Devices License Class II " in 2012
"An optimized in vitro nucleate isolation kit and method of use" granted the patent in 2012
AVIC BIOLOGY has won the financial support of the "International Strategic Emerging Industries Project" in 2013
It’s approved "Research Center on Clinical Grade Cell Therapy Technology in Ningxia Hui Autonomous Region" in 2013
It’s approved the EU Patent of "Industrial preparation of natural killer cells (NK) and injections of human allogeneic nucleated cells" in 2017
The National Development and Reform Commission approved the establishment of the "National Clinical Research Center for Cell Therapy Technology" in 2015
Mr. Wang Huailin, Chairman of AVIC BIOLOGY, won the “Chinese Patent Excellence Award" in 2015
AVIC BIOLOGY signed the strategic cooperation agreement with VITA34 Germany in 2015
"Nuclear Cell Isolating Reagent Kit" obtained national secondary medical device registration certificate
AVIC BIOLOGY listed on the New OTC Market in 2016, stock code: 839627
Western (Ningxia) human tissue cell bank officially opened in 2017
It’s approved the EU Patent of "Industrial preparation of natural killer cells (NK) and injections of human allogeneic nucleated cells" in 2017
Development history
Twenty-nine years have witnessed our development from being born to being transformed, from ignorance to maturity, and from being a boat to becoming a giant.
1.Ningxia Zhonglianda Biological Co., Ltd. (now renamed as China National Aviation (Ningxia) Biological Co., Ltd.) was formally established.
"Bone marrow blood, peripheral blood, umbilical cord blood cell processing kit" began research and development.
"A nuclear cell in vitro isolation kit and its application method" has been granted patent authorization.
"Nuclear cell processing kit" has been approved by Ningxia food and drug administration.
"A method for separating and extracting stem cells from the placenta, umbilical cord, or adipose tissue species" issued the patent in 2009
It’s approved "High-tech Enterprise in Ningxia Hui Autonomous Region " in 2011
Biomedical Engineering Academician Workstation in Ningxia Hui Autonomous Region was established in 2011
Our company has selected China Torch Program in 2012
AVIC Capital has controlled Ningxia Zhonglianda Biological Co., Ltd., the name of our company has changed to AVIC BIOLOGY in 2012
It’s approved " Medical Devices License Class II " in 2012
"An optimized in vitro nucleate isolation kit and method of use" granted the patent in 2012
AVIC BIOLOGY has won the financial support of the "International Strategic Emerging Industries Project" in 2013
It’s approved "Research Center on Clinical Grade Cell Therapy Technology in Ningxia Hui Autonomous Region" in 2013
It’s approved the EU Patent of "Industrial preparation of natural killer cells (NK) and injections of human allogeneic nucleated cells" in 2017
The National Development and Reform Commission approved the establishment of the "National Clinical Research Center for Cell Therapy Technology" in 2015
Mr. Wang Huailin, Chairman of AVIC BIOLOGY, won the “Chinese Patent Excellence Award" in 2015
AVIC BIOLOGY signed the strategic cooperation agreement with VITA34 Germany in 2015
"Nuclear Cell Isolating Reagent Kit" obtained national secondary medical device registration certificate
AVIC BIOLOGY listed on the New OTC Market in 2016, stock code: 839627
Western (Ningxia) human tissue cell bank officially opened in 2017
It’s approved the EU Patent of "Industrial preparation of natural killer cells (NK) and injections of human allogeneic nucleated cells" in 2017
Copyright © 2018 中航（宁夏）生物股份有限公司
